Neuren Pharmaceuticals Limited
NURPF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $28,277 | $192,505 | $24,327 | $168,999 |
| % Growth | -85.3% | 691.3% | -85.6% | – |
| Cost of Goods Sold | $14,897 | $15,081 | $17,889 | $15,662 |
| Gross Profit | $13,380 | $177,424 | $6,438 | $153,337 |
| % Margin | 47.3% | 92.2% | 26.5% | 90.7% |
| R&D Expenses | $14,897 | $15,081 | $17,889 | $15,662 |
| G&A Expenses | $2,483 | $2,327 | $2,374 | $3,287 |
| SG&A Expenses | $2,483 | $2,327 | $2,374 | $2,241 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$1,046 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $17,380 | $17,408 | $20,263 | $17,903 |
| Operating Income | -$4,000 | $160,016 | -$13,825 | $136,090 |
| % Margin | -14.1% | 83.1% | -56.8% | 80.5% |
| Other Income/Exp. Net | $23,721 | $11,081 | $25,668 | $4,416 |
| Pre-Tax Income | $19,721 | $171,097 | $11,843 | $155,501 |
| Tax Expense | $4,690 | $37,070 | $3,827 | $46,225 |
| Net Income | $15,031 | $134,027 | $8,016 | $109,276 |
| % Margin | 53.2% | 69.6% | 33% | 64.7% |
| EPS | 0.12 | 1.03 | 0.063 | 0.86 |
| % Growth | -88.3% | 1,540.1% | -92.7% | – |
| EPS Diluted | 0.12 | 1.03 | 0.061 | 0.83 |
| Weighted Avg Shares Out | 129,023 | 130,747 | 127,674 | 127,266 |
| Weighted Avg Shares Out Dil | 128,991 | 130,740 | 130,819 | 131,086 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6,293 | $5,178 | $5,836 | $5,003 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $11 | $11 | $11 | $11 |
| EBITDA | $10,908 | $175,108 | $4,075 | $151,096 |
| % Margin | 38.6% | 91% | 16.8% | 89.4% |